BRIEF published on 06/04/2024 at 19:35, 5 months 16 days ago Crossject Announces Successful Closing of €8 Million Rights Offering FDA Approval Rights Offering Crossject ZEPIZURE® Epilepsy Treatment
PRESS RELEASE published on 06/04/2024 at 19:30, 5 months 16 days ago Crossject announces highly successful closing of its €8 million rights offering Crossject successfully closes €8 million rights offering, securing funding for ZEPIZURE® development and FDA approval. Gemmes Venture remains a key supporter FDA Approval Rights Offering Crossject ZEPIZURE® Gemmes Venture
BRIEF published on 05/30/2024 at 10:35, 5 months 22 days ago Crossject: Publication of Clinical Data on ZEPIZURE® Crossject ZEPIZURE® Neurology And Therapy Midazolam Needle-free Injection
PRESS RELEASE published on 05/30/2024 at 10:30, 5 months 22 days ago Crossject announces publication of clinical data on ZEPIZURE ® in Neurology and Therapy Crossject announces publication of clinical data on ZEPIZURE in Neurology and Therapy, highlighting bioequivalence versus Dormicum, early onset, and low variability Clinical Data Crossject Neurology And Therapy ZEPIZURE Needle-free Auto-injector
Published on 11/21/2024 at 14:00, 11 minutes ago Demotech, Inc. Assigns a Financial Stability Rating(R) of A, Exceptional, to Steadily Insurance Company
Published on 11/21/2024 at 14:00, 11 minutes ago Montara Raises $5.4M to Help Organizations Deliver Better Data Products Faster
Published on 11/21/2024 at 14:00, 11 minutes ago Tevir Capital LP Ltd. Updates Early Warning Reporting in Respect of VerticalScope Holdings Inc.
Published on 11/21/2024 at 13:30, 41 minutes ago AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Published on 11/21/2024 at 12:35, 1 hour 36 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 56 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 06:58, 7 hours 13 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 51 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 26 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 26 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
